Case Report: COVID-19 Associated Renal Infarction and Ascending Aortic Thrombosis

Aveek Mukherjee,* Raisa Ghosh, and Marlene Marte Furment
Division of Internal Medicine, Rutgers Robert Wood Johnson Medical School/Saint Peter’s University Hospital, New Brunswick, New Jersey

Abstract. Following its discovery in Wuhan, China, in December 2019, COVID-19 has attained pandemic status in mere months. It is caused by SARS-CoV-2, an enveloped beta coronavirus. This infection causes a prothrombogenic state by interplay of inflammatory mediators, and endothelial, microvascular, and possible hepatic damage and tissue tropism of the virus. This leads to frequent pulmonary and cerebral thromboembolism as well as occasional involvement of other organs. We present a 71-year-old man who initially presented with 2 weeks of fever, cough, and shortness of breath and was diagnosed with COVID-19 pneumonia. He required readmission due to worsened hypoxia and was later found to have left renal artery thrombosis with left kidney infarction, associated with an ascending aortic thrombus. He was anticoagulated and recovered uneventfully. We suggest that physicians have a high degree of suspicion to diagnose and manage the novel manifestations of this disease.

INTRODUCTION

After its discovery in Wuhan, China, in December 2019, COVID-19 has become a pandemic in just months. COVID-19 commonly presents with fever (88.7%), cough (67.8%), fatigue (38.1%), sputum production (33.7%), shortness of breath (18.7%), and myalgia (14.9%), whereas nausea or vomiting (5%) and diarrhea (3.8%) are uncommon.1-3 COVID-19 infection has been found to be a prothrombogenic state.4-5

We present a 71-year-old man who initially presented with 2 weeks of fever, cough, and shortness of breath. He was diagnosed with COVID-19 multifocal pneumonia and required readmission due to worsening hypoxia. During his second hospitalization, he had left flank pain and was found to have left renal artery thrombi with left kidney infarction associated with an ascending aortic thrombus. He was anticoagulated with intravenous heparin infusion and transitioned to oral apixaban on discharge after an uneventful recovery.

CASE

A 71-year-old man with no significant past medical history presented with 2 weeks of fever, cough, shortness of breath, and chest discomfort with coughing in early April 2020 at a tertiary care hospital in New Brunswick, NJ. He was exposed to his daughter who was diagnosed with COVID-19 pneumonia a week before he fell ill. On presentation, he was afebrile at 99.7°F (37.6°C), blood pressure was 134/67 mmHg, tachycardic with a pulse of 112/minute, tachypneic at 34 breaths/minute, and hypoxic to 88% on 4 L/minute of oxygen via NC. Examination still noted bilateral crackles in all lung fields. Repeat investigations revealed positive COVID-19 test, persistent absolute lymphopenia and elevation of D-dimer, LDH, ferritin, and CRP (Table 1). A repeat chest X-ray showed worsened bilateral patchy opacities (Figure 1B). Saturation improved to 92% on 6 L/minute of oxygen supplementation. Hydroxychloroquine therapy was discontinued because of elevated QTc of 505 milliseconds. With worsening COVID-19 pneumonia, we initiated methylprednisolone 40 mg intravenously twice daily, along with lopinavir–ritonavir 400–100 mg orally twice daily and enoxaparin 40 mg subcutaneously twice daily. A computed tomography–pulmonary angiogram was negative for pulmonary embolism (PE) but revealed extensive multilobar ground-glass opacities (Figure 1C). Because of persistent dyspnea and hypoxia in the next 2 days, he was intermittently prone while on 6 L/minute oxygen via NC, and maintained saturation of 90–92%. Laboratory parameters were repeated intermittently as noted in Table 1. On day #9 since initial presentation, the patient complained of sharp left iliac fossa and left flank pain, which was high grade (8/10), constant, and radiating to his back, associated with nausea but no vomiting, diarrhea, dysuria, hematuria, fever, chills, or rigors. Urinalysis revealed clear, straw-colored, non-bloody urine with 30 mg/dL protein. An urgent computed tomography angiogram (CTA) revealed left superior renal artery thrombi with infarcts in the posterior mid-pole of the left kidney (Figure 2A, C, and D). The CTA also revealed ascending aortic thrombosis (Figure 2B). Bilateral lower extremity ultrasound was negative for deep venous thrombosis (DVT). We initiated heparin intravenous infusion for therapeutic anticoagulation and discontinued enoxaparin. A loading dose of clopidogrel 300 mg was given and continued with 75 mg daily. On surgical review, no intervention was advised. The next day, the abdominal pain had resolved, but we discontinued lopinavir–ritonavir as the hepatic enzymes were rising. The oxygen requirement decreased to 4 L/minute by day #12 since presentation, and we switched to apixaban 5 mg orally twice daily

* Address correspondence to Aveek Mukherjee, Division of Internal Medicine, Rutgers Robert Wood Johnson Medical School/Saint Peter’s University Hospital, 254 Easton Ave., New Brunswick, NJ 08901. E-mail: aveek8@gmail.com

1. American Journal of Tropical Medicine and Hygiene. doi:10.4269/ajtmh.20-0869
2. 1989
for anticoagulation. The patient continued to steadily recover, with improving inflammatory and renal markers (Table 1). The urine output and electrolytes remained normal throughout (Table 1). By day #14 since initial presentation, the patient was with a saturation of 90% on room air at rest, only requiring supplemental oxygen on mobilization, and corticosteroids were discontinued. The next day, he was discharged home with home oxygen therapy and 3 months of apixaban and clopidogrel regimen.

DISCUSSION

COVID-19 is caused by SARS-CoV-2, an enveloped beta coronavirus. Our knowledge regarding the pathophysiology of SARS-CoV-2 infection is still evolving. The SARS-CoV-2 infection activates an inflammatory response, releasing inflammatory mediators and activating the endothelium and hemostatic systems, with a concomitant increase of the von Willebrand factor and tissue factor.2 This manifests with a prominent elevation of D-dimer and fibrin/fibrinogen degradation products, whereas abnormalities in other coagulation parameters and platelet counts are relatively uncommon in the initial phases.4,6,7 Later, the complement pathway and cytokines like interleukin-6 (IL-6) are also involved, further activating the procoagulant pathway.4 In addition, SARS-CoV-2 has been detected in the pharynx, heart, liver, brain, kidney, and blood.8 It might infect endothelial cells via cluster of differentiations (CD13) and angiotensin converting enzyme 2 (ACE2) receptors, resulting in diffuse endothelial inflammation and microvascular damage, which can result in widespread thrombosis; however, endothelial infection has been contested.2,4,7,9–11 Other proteins, such as transmembrane serine protease 2, sialic acid receptors, extracellular matrix metalloproteinase inducer (CD147 or basigin), and cathepsins B and L are all known as possible mediators facilitating SARS-CoV-2 entry in host cells, and are also expressed in endotheliocytes.7 This prothrombotic state may be further potentiated by an underlying viral hepatic dysfunction/damage with decreased antithrombin production.2,6 This results in disruption of the natural antithrombotic state.4 Occasionally, because of unclear mechanisms, the inflammatory response is severe, resulting in a dysregulated release of mediators like IL-6 (“cytokine storm”), resulting in magnified pathophysiology. Anti-phospholipid antibodies (APLAs) have also been detected in some COVID-19 patients, which may lead to thrombotic events similar to antiphospholipid syndrome.12 Hence, we can infer how the interplay between the aforementioned factors leads to COVID-19–induced thromboembolic complications.

Renal infarction is relatively rare, with an incidence of 0.1–1.4%.13,14 Risk factors include male gender, hypertension, peripheral arterial disease, hyperlipidemia, and smoking.14,15 Etiology includes embolization, in situ thrombosis of the renal artery, renal artery dissection, fibromuscular dysplasia, hypercoagulability,
and following endovascular interventions. Most patients have abdominal or flank pain, and, occasionally, fever, nausea, uncontrolled hypertension, hematuria, or acute renal failure. The rarity of the condition along with the non-specific presentation makes diagnosis challenging. Imaging is essential for diagnosis, with contrast-enhanced computed tomogram (CT) being preferable; however, angiography remains gold standard.

Before, in a series of two cases with renal infarcts in patients with COVID-19, one presented with acute kidney injury (AKI), whereas the other had AKI with associated bowel ischemia. It has also been found in a kidney transplant recipient without any arterial or venous thrombi. In another patient, the renal infarct was associated with renal artery thrombosis; however, the renal function remained normal, similar to our patient.

Severe infections with viruses such as influenza, pandemic H5N1/H1N1 influenza, parvovirus B19, cytomegalovirus, Epstein–Barr virus, hepatitis C, dengue, and chikungunya have been associated with thromboembolism and associated renal dysfunction. COVID-19–associated aortic thrombosis has been found in association with PE, acute limb ischemia, DVT, acute mesenteric ischemia, and stroke. Severe and fatal cerebral venous thrombosis has also been noted.

In our patient, we hypothesized that severe COVID-19 pneumonia induced a prothrombotic state, resulting in the ascending aortic thrombosis. This thrombus likely embolized, or there could have been an isolated neo-thrombosis in the renal artery as well. This thromboembolic pathology manifested with renal infarction. We treated our patient with hydroxychloroquine and later lopinavir–ritonavir as per existing institutional protocols; however, this regimen was later deemed controversial in the literature. Corticosteroid therapy can lower mortality. Prone positioning of awake, non-intubated patients may improve oxygenation. Antiphospholipid antibodies were not tested in our patient. For anticoagulation, the guidelines proposed by the anticoagulation forum, the American College of Cardiology, and the International Society of Thrombosis and Haemostasis were followed. For noncritically ill hospitalized patients, a standard regimen of venous thromboembolism prophylaxis is recommended. For critically ill patients, higher doses are recommended based on expert opinion. Regimens may include enoxaparin 0.5 mg/kg subcutaneous twice daily, heparin 7,500 units subcutaneous three times daily, or low-intensity heparin infusion. This was instituted in our patient’s second hospitalization. For the treatment of arterial thrombosis, the patient was put on a heparin infusion. On discharge, a 45- to 90-day course of therapeutic anticoagulation is recommended depending on risk.

In conclusion, the thromboembolic consequences of COVID-19 can occasionally result in rare complications such as aortic thrombosis and renal infarction. During a pandemic, we advise that the physicians should maintain a high degree of clinical suspicion to diagnose rare manifestations of this novel disease for timely management.

Received July 16, 2020. Accepted for publication September 1, 2020. Published online September 10, 2020.

Acknowledgment: Publication charges for this article were waived due to the ongoing pandemic of COVID-19.

Authors’ addresses: Aveek Mukherjee, Raisa Ghosh, and Marlene Marte Furment, Division of Internal Medicine, Rutgers Robert Wood Johnson Medical School/Saint Peter’s University Hospital, New Brunswick, NJ. E-mails: aveek8@gmail.com, ghosh.raisa@gmail.com and mmartefurment@saintpetersuh.com.
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Guan W et al., 2020. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 382: 1708–1720.

2. Bikdeli B et al.; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, 2020. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 75: 2950–2973.

3. Barnes GD et al., 2020. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 50: 72–81.

4. Connors JM, Levy JH, 2020. COVID-19 and its implications for thrombosis and anticoagulation. Blood 135: 2033–2040.

5. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T, 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 18: 1023–1026.

6. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL, 2020. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 58: 1116–1120.

7. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G, 2020. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med 9: 1417.

8. Puellas VG et al., 2020. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 383: 590–592.

9. Varga Z, Flammer AJ, Steiger P, Haberecker K, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H, 2020. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395: 1417–1418.

10. Goldsmith CS, Miller SE, Martines RB, Bullock HA, Zaki SR, 2020. Electron microscopy of SARS-CoV-2: a challenging task. Lancet 395: e99.

11. Frelin M, Erman A, Wechtshersbach K, Plesko J, Avsić-Županc T, Kocj N, 2020. SARS-Cov-2 virions or ubiquitous cell structures? Actual dilemma in COVID-19 era. Kidney Int Rep 5: 146–150. doi: 10.1016/j.ekir.2020.07.003.

12. Zhang Y et al., 2020. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med 382: e38.

13. Caravaca-Fontán F, Pampa Saico S, Elias Triviño S, Galeano Álvarez C, Gomis Couto A, Pecharramón de las Heras I, Liaoño F, 2016. Acute renal infarction: clinical characteristics and prognostic factors. Nefrologia 36: 141–148.

14. Faucon AL, Bobrie G, Iannot AS, Azarine A, Plouin PF, Azzini M, Amar L, 2018. Cause of renal infarction: a retrospective analysis of 186 consecutive cases. J Hypertens 36: 634–640.

15. Silverberg D, Menes T, Rimon U, Salomon O, Halak M, 2016. Acute renal artery occlusion: presentation, treatment, and outcome. J Vasc Surg 64: 1026–1032.

16. Post A, den Deurwaarder ESG, Bakker SJL, de Haas RJ, van Meurs M, Gansevoort RT, Berger SP, 2020. Kidney infarction in patients with COVID-19. Am J Kidney Dis 76: 431–435.

17. Xu JJ, Samaha D, Mondhe S, Massicotte-Azarniouch D, Knoll G, Ruzicka M, 2020. Renal infarct in a COVID-19–positive kidney-pancreas transplant recipient. Am J Transplant 1–4. doi: 10.1111/ajt.16089.

18. Tascón GC et al., 2020. Renal infarction in a patient with active COVID-19 infection. Nefrologia, doi: 10.1016/j.nefro.2020.04.008.

19. Goejenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VEA, Meijers JCM, Brandjes DPM, van Gorp ECM, 2012. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol 84: 1680–1696.

20. Canpolat N, Topal N, Celiktas M, Caliskan S, Sever L, Kasapcopur O, Baserer T, Arsnoy N, 2008. A case of catastrophic antiphospholipid syndrome in an adolescent girl with parvovirus B19 infection. Clin Pediatr (Philadelphia) 47: 593–597.

21. Baid S, Pascual M, Williams WW, Tol Kok-Rubin N, Johnson SM, Collins B, Chung RT, Delmonico FL, Cosimi AB, Colvin RB, 1999. Renal thrombotic microangiopathy associated with antiphospholipid antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 10: 146–153.

22. Ramacciotti E et al., 2019. Zika and chikungunya virus and risk for venous thromboembolism. Clin Appl Thromb Hemost 25: 1076029618821184.

23. Bunce PE, High SM, Nadji J, Stanely K, Liles WC, Christian MD, 2011. Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 52: e14–e17.

24. Le Berre A, Marteau V, Emmerich J, Zins M, 2020. Comorbid acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. Diagn Interv Imaging 101: 321–322.

25. Gomez-Arbelaez D, Ibarra-Sanchez G, Garcia-Gutierrez A, Comanges-Yeboles A,Ansuatxegui-Vicente M, Gonzalez-Fajardo JA, 2020. COVID-19-Related aortic thrombosis: a report of four cases. Ann Vasc Surg 67: 10–13.

26. Cavalcanti DD et al., 2020. Cerebral venous thrombosis associated with COVID-19. AJNR Am J Neuroradiol 41: 1370–1376.

27. Mukherjee A, Ahmad M, Frenia D, 2020. A Coronavirus disease 2019 (COVID-19) patient with multifocal pneumonia treated with hydroxychloroquine. Cureus 12: e7473.

28. Gao B et al., 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 382: 1787–1799.

29. Geleris J et al., 2020. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 382: 2411–2418.

30. Rosenberg ES et al., 2020. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 323: 2493–2502.

31. Arshad S et al.; Henry Ford COVID-19 Task Force, 2020. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 97: 396–403.

32. Horby P et al.; RECOVERY Collaborative Group, 2020. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med, doi: 10.1056/NEJMoa2021436.

33. Thompson AE, Ranard BL, Wei Y, Jelic S, 2020. Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure. JAMA, doi: 10.1001/jama.2020.3303.

34. Elharrar X, Trigui Y, Dols AM, Touchon F, Martinez S, Prudhomme E, Papazian L, 2020. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. JAMA 323: 2336–2338.